Evidence map›Paper›PMID 25516711›Full record

ArticleNeuropsychiatric disease and treatment2014

Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke.

Mohammad Reza Amiri-Nikpour, Surena Nazarbaghi, Babak Ahmadi-Salmasi, Tayebeh Mokari, Urya Tahamtan, Yousef Rezaei

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychiatric disease and treatment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 8 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 8 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Cerebrolysin for acute ischaemic stroke.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Cerebrolysin for acute ischaemic stroke.The Cochrane database of systematic reviews · 2020
    Pooled it
  4. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018
    Pooled it
  5. Cerebrolysin for acute ischaemic stroke.The Cochrane database of systematic reviews · 2017
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Cerebrolysin for acute ischaemic stroke.The Cochrane database of systematic reviews · 2016
    Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Observational
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mohammad Reza Amiri-NikpourDepartment of Neurology, Imam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran.
Surena NazarbaghiDepartment of Neurology, Imam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran.
Babak Ahmadi-SalmasiDepartment of Neurology, Imam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran.
Tayebeh MokariSchool of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Urya TahamtanSchool of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Yousef RezaeiSeyyed-al-Shohada Heart Center, Urmia University of Medical Sciences, Urmia, Iran.
Imam Khomeini Hospital · IRUrmia University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCerebrolysin, a brain-derived neuropeptide, has been shown to improve the neurological outcomes of stroke, but no study has demonstrated its effect on cerebral blood flow. This study aimed to determine the cerebrolysin impact on the neurological outcomes and cerebral blood flow.

methodsIn a randomized, double-blinded, placebo-controlled trial, 46 patients who had acute focal ischemic stroke were randomly assigned into two groups to receive intravenously either 30 mL of cerebrolysin diluted in normal saline daily for 10 days (n=23) or normal saline alone (n=23) adjunct to 100 mg of aspirin daily. All patients were examined using the National Institutes of Health Stroke Scale and transcranial Doppler to measure the mean flow velocity and pulsatility index (PI) of their cerebral arteries at baseline as well as on days 30, 60, and 90.

resultsThe patients' mean age was 60±9.7 years, and 51.2% of patients were male. The National Institutes of Health Stroke Scale was significantly lower in the cerebrolysin group compared with the placebo group on day 60 (median 10, interquartile range 9-11, P=0.008) and day 90 (median 11, interquartile range 10-13.5, P=0.001). The median of PI in the right middle cerebral artery was significantly lower in the cerebrolysin group compared with the placebo group on days 30, 60, and 90 (P<0.05). One patient in the cerebrolysin group and two patients in the placebo group died before day 30 (4.3% versus 8.7%).

conclusionCerebrolysin can be useful to improve the neurological outcomes and the PI of middle cerebral artery in patients with acute focal ischemic stroke.

Indexed as

cerebrolysinischemic strokemean flow velocityneuroprotectionNIHSSpulsatility index

Identifiers

PMID25516711
PMCPMC4263193
OpenAlexW2144495723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.